Results 111 to 120 of about 12,593 (182)

Effects of pirfenidone on experimental head injury in rats

, 2022
Traumatic brain injury (TBI) continues to be a significant public healthcare concern. Neuroinflammation that occurs in the secondary phase of TBI leads to cognitive and physical dysfunction.
GÜVENÇ, YAHYA, Ozturk, Yasar, Bozkurt, Ismail, Arslan, Burak, GÜLBAHAR, ÖZLEM, Senturk, Salim, GÜNEY, GÜVEN, YAMAN, MESUT EMRE   +7 more
core  

Issue Information

Experimental Physiology, Volume 111, Issue 10, Page 4949-4954, 1 October 2026.
wiley   +1 more source

Case Report: Pirfenidone-Induced Toxic Epidermal Necrolysisa a Rare Idiosyncratic Reaction

Clinical, Cosmetic and Investigational Dermatology
Mingang Zhu,1 Yin Wang,1 Sheng Wei,1 Guang Chen,2 Er-Min Gu3 1Department of Dermatology, The First People’s Hospital of Jiashan, Jiashan Hospital Affiliated of Jiaxing University, Jiaxing, 314100, People’s Republic of China; 2Department of Pathogenic ...
Zhu M, Wang Y, Wei S, Chen G, Gu EM
doaj  

Comparative Clinical Outcomes of Nintedanib and Pirfenidone in Idiopathic Pulmonary Fibrosis: A Five-year Real-life Study. [PDF]

Thorac Res Pract
Mammadova A.
europepmc   +1 more source

Cost-effectiveness of pirfenidone for patients with cancer and grade 2 or grade 3 radiation-induced lung injury: A modeling study. [PDF]

PLoS Med
Pan QY, Wang YX, Tang XY, Hou Z, Dong BQ, Li QW, Chen BQ, Bai SM, Wu CF, Chen M.   +9 more
europepmc   +1 more source

Gut microbiota associate with disease severity and survival in idiopathic pulmonary fibrosis. [PDF]

Am J Respir Crit Care Med
Kim JS, Loe A, Ma SF, Ranjan P, Lipinski JH, Mikhail SG, Gurczynski SJ, Zhou X, Huffnagle GB, Downward JE, Metcalf JD, Falkowski N, Stringer KA, Dickson RP, Huang Y, Moore BB, Martinez FJ, Murray S, Noth I, O'Dwyer DN.   +19 more
europepmc   +1 more source

Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial. [PDF]

Am J Respir Crit Care Med
Maher TM, Hamblin MJ, Choi WI, Case AH, Tomos IP, Tzouvelekis AE, Shore JE, Bergna MA, Golod D, Elenko E, Zhang Y, Graham CS, Song JW, Kulkarni T, and the ELEVATE IPF Investigators.   +14 more
europepmc   +1 more source

Pirfenidone Modulates Airway Responsiveness, Inflammation, and Remodeling after Repeated Challenge

We investigated the therapeutic potential of a newly developed antifibrotic agent, pirfenidone, to regulate airway remodeling and the development of allergic airway inflammation and airway hyperresponsiveness after chronic allergen challenge ...
平野, 淳
core  

Pamufetinib (TAS-115) for chronic fibrosing interstitial lung diseases with a progressive phenotype: a double-blind, multicenter, phase 2b clinical trial. [PDF]

Am J Respir Crit Care Med
Okuda R, Nishioka Y, Kondoh Y, Tsubouchi K, Okamoto M, Nishiyama O, Sato S, Oishi K, Ishikawa N, Chiba H, Miyazaki Y, Homma S, Ogura T, Inoue Y, Azuma A.   +14 more
europepmc   +1 more source

Engineered bacteria reverses tumor cuproptosis resistance via cancer-associated fibroblast reprogramming for enhanced immunotherapy. [PDF]

Mater Today Bio
Chen Y, Geng X, Su N, Saw PE, Li Y, Liu B, Li Y, Yuan Z.   +7 more
europepmc   +1 more source